@article{23cabaa5dbd44cdab32ed0df14859ed9,
title = "Does Sex Modify the Effect of Endovascular Treatment for Ischemic Stroke?: A Subgroup Analysis of 7 Randomized Trials",
abstract = "Background and Purpose- Previous studies have reported less favorable outcome and less effect of endovascular treatment (EVT) after ischemic stroke in women than in men. Our aim was to study the influence of sex on outcome and on the effect of EVT for ischemic stroke in recent randomized trials on EVT. Methods- We used data from 7 randomized controlled trials on EVT within the HERMES collaboration. The primary outcome was 90-day functional outcome (modified Rankin Scale). We compared baseline characteristics and outcomes between men and women. With ordinal logistic regression, we evaluated the association between EVT and 90-day functional outcome for men and women separately, adjusted for potential confounders. We tested for interaction between sex and EVT. Results- We included 1762 patients in the analyses, of whom 833 (47%) were women. Women were older (median, 70 versus 66 years; P",
keywords = "randomized controlled trial, sex, stroke, thrombectomy, INTRAARTERIAL TREATMENT, INTRAVENOUS ALTEPLASE, CLINICAL PRESENTATION, GENDER-DIFFERENCES, COLLATERAL STATUS, ARTERY-OCCLUSION, THROMBECTOMY, OUTCOMES, THROMBOLYSIS, ANGIOGRAPHY",
author = "Vicky Chalos and {de Ridder}, {Inger R.} and Lingsma, {Hester F.} and Scott Brown and {van Oostenbrugge}, {Robert J.} and Mayank Goyal and Campbell, {Bruce C. V.} and Muir, {Keith W.} and Francis Guillemin and Serge Bracard and Philip White and Antoni Davalos and Jovin, {Tudor G.} and Hill, {Michael D.} and Mitchell, {Peter J.} and Demchuk, {Andrew M.} and Saver, {Jeffrey L.} and {van Zwam}, {Wim H.} and Dippel, {Diederik W. J.} and {HERMES Collaboration}",
note = "Funding Information: Dr Brown reports personal fees from the University of Calgary during the conduct of the HERMES collaboration (Highly Effective Reperfusion Using Multiple Endovascular Devices) and personal fees from Medtronic outside the submitted work. Dr Goyal reports that Medtronic provided a grant to the University of Calgary toward the HERMES collaboration and that Stryker provided a research grant to the University toward the UNMASK EVT study (Decision Making Under Uncertainty in the Management of Acute Stroke With Endovascular Thrombectomy: Applying Principles From Neuroeconomics). Dr Muir reports grants from Medtronic and Codman outside the submitted work and has an advisory relationship with Boehringer Ingelheim. Dr White has consulted for Microvention, Codman, and Stryker. Dr D{\'a}valos reports consultancy and advisory board fees from Medtronic Neurovascular (Steering Committee STAR [Solitaire FR Thrombectomy for Acute Revascularization]) and an unrestricted grant for the REVASCAT trial (Randomized Trial of Revascularization With Solitaire FR Device versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting Within 8 Hours of Symptom Onset) from Medtronic (paid to his institution). Dr Jovin has consulted for Cerenovus as Data Safety Monitoring Board/steering committee and Stryker Neurovascular as a principal investigator of the DAWN trial (DWI or CTP Assessment With Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo); received honoraria from Biogen as a consultant; holds stock or other ownership at Silk Road, Anaconda, Route 92, Corindus, Blockade Medical, and FreeOx Biotech. Dr Hill reports a research grant from Medtronic LCC paid to the University of Calgary for the HERMES collaboration. Dr Mitchell reports speaking engagements from Stryker and Microvention and honoraria from Stryker, outside the submitted work. Dr Demchuk reports honoraria from Medtronic during the conduct of the HERMES collaboration. Dr Saver has acted as a scientific consultant regarding trial design and conduct for Medtronic, Stryker, Cerenovus, and Rapid Medical and reports that the University of California has patent rights in the retrieval devices for stroke. Dr van Zwam reports speaking engagements from Stryker and Cerenovus (both paid to his institution). Dr Dippel reports research grants from the Dutch Heart Foundation, Dutch Brain Foundation, the Netherlands Organisation for Health Research and Development, Health Holland Top Sector Life Sciences and Health, and unrestricted grants from AngioCare BV, Medtronic/ Covidien/EV3, MEDAC Gmbh/LAMEPRO, Penumbra, Inc, Stryker, Stryker European Operations BV, Top Medical/Concentric, and Thrombolytic Science, LLC (all paid to his institution). The other authors report no conflicts. Publisher Copyright: {\textcopyright} 2019 The Authors.",
year = "2019",
month = sep,
doi = "10.1161/STROKEAHA.118.023743",
language = "English",
volume = "50",
pages = "2413--2419",
journal = "Stroke",
issn = "0039-2499",
publisher = "Wolters Kluwer Health",
number = "9",
}